Menu Search
Equities

Glaukos Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6GJ:MUN

Glaukos Corp

Actions
  • Price (EUR)96.00
  • Today's Change0.00 / 0.00%
  • Shares traded100.00
  • 1 Year change-34.69%
  • Beta0.7072
Data delayed at least 15 minutes, as of Feb 11 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

  • Revenue in USD (TTM)469.82m
  • Net income in USD-87.61m
  • Incorporated1998
  • Employees995.00
  • Location
    Glaukos Corp1 GLAUKOS WAYALISO VIEJO 92656United StatesUSA
  • Phone+1 (949) 367-9600
  • Fax+1 (949) 367-9984
  • Websitehttps://www.glaukos.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		GKOS:NYQ since
announced		Transaction
value
Mobius Therapeutics IncDeal completed01 Aug 202501 Aug 2025Deal completed26.65%--
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.